ArticleHuman vaccines & immunotherapeutics2019
Increase in incidence of invasive pneumococcal disease caused by serotype 3 in children eight years after the introduction of the pneumococcal conjugate vaccine in Hong Kong.
Article in Human vaccines & immunotherapeutics, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 1 synthesis or guideline pooled it.
- The impact of the introduction of ten- or thirteen-valent pneumococcal conjugate vaccines on antimicrobial-resistant pneumococcal disease and carriage: A systematic literature review.Journal of global health · 2023Pooled it
- Impact of CRM197-based conjugate vaccines, schedules, and regions on pneumococcal immunogenicity in young children: systematic review.NPJ vaccines · 2026Article
- Preliminary genomic assessment of invasive Streptococcus pneumoniae serotype 3 isolates in Malaysia.BMC genomic data · 2026Article
- Association between introduction of 13-valent pneumococcal conjugate vaccine and burden of hospitalized adult pneumococcal disease in Hong Kong - A retrospective database study.Human vaccines & immunotherapeutics · 2025Article
- The microbiological characteristics and diagnosis ofHuman vaccines & immunotherapeutics · 2025Review
- Optimizing Neutrophil Recruitment to Tackle Bacterial Infections.American journal of respiratory cell and molecular biology · 2025Article
- Changes in the incidence, viral coinfection pattern and outcomes of pneumococcal hospitalizations during and after the COVID-19 pandemic.Pneumonia (Nathan Qld.) · 2025Article
- Article
- Changes in Etiology and Clinical Outcomes of Pleural empyema during the COVID-19 Pandemic.Microorganisms · 2023Article
- Health and economic burden associated with 15-valent pneumococcal conjugate vaccine serotypes in Korea and Hong Kong.Human vaccines & immunotherapeutics · 2022Article
- Impact of national pneumococcal vaccination program on invasive pneumococcal diseases in South Korea.Scientific reports · 2022Article
- Article
- Substantial Decline in Invasive Pneumococcal Disease During Coronavirus Disease 2019 Pandemic in Hong Kong.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2022Article
- Epidemiology of non-vaccine serotypes ofHuman vaccines & immunotherapeutics · 2021Review
- Observational
- Genotypic and phenotypic characteristics of Streptococcus pneumoniae from community-acquired pneumonia patients and healthy asymptomatic participants in Sichuan province, China.BMC infectious diseases · 2021Article
- Global genomic pathogen surveillance to inform vaccine strategies: a decade-long expedition in pneumococcal genomics.Genome medicine · 2021Review
- Serotype distribution and clinical characteristics associated withHuman vaccines & immunotherapeutics · 2021Observational
- Antibiotic Resistance and Molecular Biological Characteristics of Non-13-Valent-Pneumococcal Conjugate Vaccine Serogroup 15Frontiers in microbiology · 2021Article
- Characteristics of Serotype 3 Invasive Pneumococcal Disease before and after Universal Childhood Immunization with PCV13 in Massachusetts.Pathogens (Basel, Switzerland) · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
This study used several datasets of reported and serotyped invasive pneumococcal disease (IPD) cases to estimate vaccine and non-vaccine type incidence in Hong Kong children. Incidence was analyzed by four time periods to indicate pre-PCV (period 1, 1995-2004), private market only (period 2, 2006-2009), and following early (period 3, 2010-2014, mixed use of 7-, 10- and 13-valent vaccines) and more than five years (period 4, 2015-2017, 13-valent vaccine only) of routine implementation (since September 2009). IPD incidence decreased by 85% and 35% in aged < 2 years and aged 2 to < 5 years, respectively, from period 1 to period 4. This was due to a 97% reduction in the serotypes covered by 7-valent vaccine. In period 4, 59% of the disease was caused by serotype 3 and was largely attributed to an ermB positive, novel ST6011 clone. The finding corroborates an increasing body of evidence that the efficacy of the 13-valent vaccine against infection by this serotype is low.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.